Premium
Prospects for a prophylactic HPV vaccine: Rationale and future implications for cervical cancer screening
Author(s) -
Sherman Mark E.,
Schiffman Mark H.,
Strickler Howard,
Hildesheim Allan
Publication year - 1998
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/(sici)1097-0339(199801)18:1<5::aid-dc2>3.0.co;2-g
Subject(s) - medicine , cervical cancer , cervical cancer screening , hpv vaccines , cervical screening , gynecology , cancer , oncology , hpv infection
Cytologic screening in combination with ablative therapy has helped reduce cervical cancer mortality in the developed world. Despite the success of this approach, cervical cancer remains a major cause of death, especially among women with limited access to health care. Recognition that human papillomaviruses (HPVs) are the main etiologic agent in cervical cancer suggests that a prophylactic vaccine could reduce the incidence of HPV infection and, therefore, achieve cancer control with reduced reliance on costly screening programs. In this review, the rationale for developing a prophylactic HPV vaccine and the potential impact that vaccination would have on cervical cancer screening are discussed. Diagn. Cytopathol. 1998;18:5–9. © 1998 Wiley‐Liss, Inc.